Kimera Labs is the leading exosome biotechnology laboratory specializing in the production of perinatal mesenchymal stem cell-derived (MSC) exosome products.
Vive is a topical solution specially developed for cosmetic purposes. The product contains proteins, enzymes, growth factors, and exosomes derived from mesenchymal stem cells (MSCs). Vive is a cell-free topical cosmetic product.
The MSC cell bank utilized in the manufacturing process is meticulously isolated from donated human placenta.
Dr. Halim’s is a Board certified Anesthesiologist as well as Aesthetic Medicine, Anti-aging and Regenerative Medicine Physician. Dr. Halim’s medical training began at Northwestern University in Chicago.
She pursued her interests in Aesthetics, Lasers, PDO Threads thereby continued to build her expertise in various areas such as facial rejuvenation, integrative/functional medicine, nutrition, and hyperbaric medicine so that she may combine this knowledge to achieve beauty from inside out with the focus being on each patient’s skincare, diet, fitness as well as lifestyle.
Dr. Halim has successfully held many roles as National Medical Director for hospital, surgical and aesthetic practice startups as part of a large Healthcare company. She runs a Medical Consulting Company, is a national speaker and educator, has been a KOL for various companies as well speaker for A4M, Boston Biolife, and CMO for Empire Medical as well as CMO for Kimera Labs.
Dr. Halim has been featured in Buzzfeed for her trademarked treatment of cellulite combining Carboxytherapy and PDO threads, also has presented at the Aesthetics Everything, the Global Aesthetics Conference and the Global Virtual Aesthetics Summit, The Aesthetic Show, Miami Cosmetic Surgery, to name a few. She has also been featured in several editorials and magazines for her expertise in beauty, wellness and skincare such as Vogue, Glamour, HuffPost, OprahDaily, GQ, Byrdie and many more.
Azza Halim, MD currently practices in Florida and Chicago as well as Newport Beach California.
Chernoff G (2021) The Utilization of Human Placental Mesenchymal Stem Cell Derived Exosomes in Aging Skin: An Investigational Pilot Study. J Surg 6: 1388. DOI: 10.29011/2575-9760.001388
Forty patients were enrolled in a randomized, double-blinded, placebo (saline) controlled study. There were 20 patients in the treatment group and 20 patients in the saline control group. Each group underwent facial microneedling with immediate topical application of either 5 billion exosomes suspended in saline, or saline alone. Treatments were repeated at 30, 60, and 90 days, with final analysis at 120 days. Standardized photography was coupled with 3-dimensional analysis utilizing the Quantificare Imaging System. Linear analog tests were also administered to objectify patient satisfaction.
There were no adverse reactions, allergic, or hypersensitivity reactions reported. The exosome treatment group showed improved tone, quality, and clarity of their skin compared to the control group (p < .0001), with a reduction in pores, pigment, oiliness, and improvement in evenness of skin. There was a constant progression of satisfaction with results in the treatment group from 30 to 120 days, compared with a high degree of dissatisfaction with results in the control group.